Group 2F: ER+ Breast Cancer; Predictive Biomarkers; Treatment Resistance

Name: Group 2F: ER+ Breast Cancer; Predictive Biomarkers; Treatment Resistance
Start: 2023-12-14
End: 2023-12-14

Poster #PO2-16-03: ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC).

Poster #PO3-23-09: ESR1 mutations drive resistance to CDK4/6 inhibitors in ER+ Breast Cancer.